IGMS 6.9 (-2.13%)
US4495851085BiotechnologyBiotechnology

IGM Biosciences (IGMS) Stock Highlights

6.9 | -2.13%
2024-12-21 04:55:05
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Statistics

Range Today
6.76 7.5
Volume Today 434.9K
Range 1 Year
6.17 22.5
Volume 1 Year 75.6M
Range 3 Year
3.81 35.98
Volume 3 Year 268.16M
Range 10 Year
3.81 133
Volume 10 Year 368.99M

Highlights

Market Capitalization 772.92M (small)
Floating Shares 11.53M
Current Price 6.9
Price To Earnings -4.33
Price To Revenue 218.28
Price To Book 3.76
Earnings Per Share -3.24
Payout Ratio 0%

Performance

Latest -2.13%
1 Month -26.2%
3 Months -60.12%
6 Months -3.5%
1 Year -10.97%
3 Years -75.22%
5 Years -81.6%
10 Years -62.32%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.